Application |
: |
Cardioselective ß1-adrenergic blocker. An antihypertensive; antiglaucoma. |
Payment mode |
: |
Credit / Debit / Purchase Order |
Taxes |
: |
All prices are inclusive taxes |
Refund Policy |
: |
30 days money back guarantee |
References |
: |
"Cadigan, P,J,, et al,: Br, J, Clin, Pharmacol,, 9, 569 (1980), Pathe, M,, et al,: Therapie, 37, 75 (1982)," |
Canonical SMILES |
: |
CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
|
Isomeric SMILES |
: |
CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O |
InChI |
: |
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3 |
InchIKey |
: |
NWIUTZDMDHAVTP-UHFFFAOYSA-N |
Related CAS |
: |
63659-19-8 (hydrochloride) |
IUPAC Name |
: |
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol |
Exact Mass |
: |
307.21474379 |
Melting Point |
: |
70-72 °C |
Use Classification |
: |
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients |
Hazard Class |
: |
Acute Tox. 4 (100%) |
Description |
: |
Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent and a sympatholytic agent. |
EC Number |
: |
613-310-1 |
Toxicity Summary |
: |
Oral LD50s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in rats. Predicted symptoms of overdose include bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia. |